Why AERASYN

An integrated approach to psychedelic-derived medicines.

AERASYN approaches psychedelic therapeutics through an engineering and development platform that connects molecule, formulation, delivery and translational execution.

A differentiated model

AERASYN Biotech vs traditional psychedelics.

AERASYN Biotech

Integrated product development

  • 01
    Vertically Integrated PlatformConnected capabilities from discovery through development.
  • 02
    Precision DeliveryFormulation and route are treated as product variables.
  • 03
    Engineered ModulationMolecular and exposure profiles are investigated deliberately.
  • 04
    AI + Translational ExecutionComputational tools support prioritization alongside experimental development.
  • 05
    Multiple Partner Entry PointsPrograms and capabilities can support scientific collaboration.
Traditional psychedelics

Conventional compound-led model

  • 01
    Single MoleculeDevelopment is concentrated around one primary compound.
  • 02
    Clinic DependentAdministration may rely on intensive treatment settings.
  • 03
    High Hallucinogenic RiskPsychoactive intensity can influence safety and treatment practicality.